The urocortins are a family of endogenously produced peptide hormones that show great promise as potential drugs for the treatment of heart disease. They can increase contractility and cardiac output without causing changes in mean arterial blood pressure. As expected, the receptor for these peptides is present in cardiomyocytes, and they can bind and protect these cells from simulated ischemia and reperfusion in vitro. The receptor is present, however, in much higher density in the endothelial cells that form a continuous lining of the coronary vasculature. Functionally, the urocortin peptides have been shown to have potent local vasodilatory effects, and may affect other aspects of vascular function. In this review, we will attempt to distinguish the "cardio" from the "vascular" effects of urocortin and its homologues, including the archetypal family member, corticotrophin releasing hormone.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1734-1140(09)70019-2 | DOI Listing |
Front Immunol
December 2024
Institute of Forensic Medicine and Laboratory Medicine, Jining Medical University, Jining, China.
The defense mechanisms of the vertebrate brain against infections are at the forefront of immunological studies. Unlike other body parts, the brain not only fends off pathogenic infections but also minimizes the risk of self-damage from immune cell induced inflammation. Some neuropeptides produced by either nerve or immune cells share remarkable similarities with antimicrobial peptides (AMPs) in terms of size, structure, amino acid composition, amphiphilicity, and net cationic charge.
View Article and Find Full Text PDFFront Behav Neurosci
January 2024
Anatomy and Cell Biology, Department of Medicine, Nara Medical University, Kashihara, Japan.
Vascul Pharmacol
March 2024
Department of Pharmacology, School of Basic Medical Sciences, Nanjing Medical University, Longmian Avenue, 101, Nanjing, China. Electronic address:
Corticotropin releasing factor family peptides (CRF peptides) include 4 members, corticotropin releasing hormone (CRH), Urocortin (UCN1), UCN2 and UCN3. CRF peptides function via the two distinct receptors, CRF and CRF. Among them, CRH/CRF has been recognized to influence immunity/inflammation peripherally.
View Article and Find Full Text PDFBiochem Pharmacol
January 2024
Department of Pharmacology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China. Electronic address:
Diabetic patients develop coronary microvascular dysfunction (CMD) and exhibit high mortality of coronary artery disease. Methylglyoxal (MGO) largely accumulates in the circulation due to diabetes. We addressed whether macrophages exposed to MGO exhibited damaging effect on the coronary artery and whether urocortin2 (UCN2) serve as protecting factors against such diabetes-associated complication.
View Article and Find Full Text PDFJ Physiol Pharmacol
February 2023
Jagiellonian University Medical College, Department of Internal Medicine and Gerontology, Cracow, Poland.
Urocortin 2, an endogenous selective ligand for the corticotropin-releasing hormone receptor type 2, has been suggested to exert cardioprotective effects. We analyzed the possible relationship between the level of Ucn2 and specific indicators of cardiovascular risk factors in patients with untreated hypertension and in healthy subjects. Sixty seven subjects were recruited: 38 with newly diagnosed treatment-naive hypertension (with no pharmacological treatment - HT group) and 29 healthy subjects without hypertension (nHT group).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!